Lymphoma

Lymphoma

A collection of features and news articles published in ASH Clinical News related to lymphoma.

WIB_icon

Risk-Adapted, Chemotherapy-Alone Treatment Strategy Effective for Early-Stage Hodgkin Lymphoma

Detection of disease on interim PET/CT scans after two cycles of chemotherapy is a powerful predictor of outcomes in patients with early-stage, non-bulky Hodgkin...

Venetoclax Approved for All Patients With Relapsed/Refractory CLL and SLL

The U.S. Food and Drug Administration (FDA) granted approval to venetoclax for the treatment of patients with previously treated chronic lymphocytic leukemia (CLL) or...

CheckMate 205: Evaluating Nivolumab in Newly Diagnosed Hodgkin Lymphoma

In a study presented by Radhakrishnan Ramchandren, MD, at the 23rd Congress of the European Hematology Association, the four-drug regimen of nivolumab plus doxorubicin,...

Updated Results from JULIET: Tisagenlecleucel Associated With Durable Responses in DLBCL

In May 2018, the U.S. Food and Drug Administration expanded the approval of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel to the treatment...

FDA Approves Pembrolizumab for Relapsed/Refractory PMBCL

Pembrolizumab was granted an accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients with refractory...

Lenalidomide Therapy Increases VTE Risk in B-Cell Non-Hodgkin Lymphoma

Patients with B-cell non-Hodgkin lymphoma (NHL) treated with lenalidomide have an increased risk of developing venous thromboembolism (VTE) – similar to the increased risk...

Ibrutinib and Venetoclax Combo Confers High Response in Mantle-Cell Lymphoma

In results from a phase II study published in The New England Journal of Medicine, the combination of the Bruton tyrosine kinase (BTK) inhibitor...

Chemotherapy-Free Combination Shows Efficacy in Untreated Follicular Lymphoma

The randomized, global, phase III RELEVANCE trial showed that a regimen of lenalidomide and rituximab (R2) had similar safety and efficacy to a rituximab-based...

Combination Brentuximab Vedotin and Bendamustine Safe and Effective for Heavily Pretreated HL

Coupling the anti-CD30 antibody drug conjugate brentuximab vedotin with bendamustine may offer an effective salvage regimen for patients with relapsed/refractory Hodgkin lymphoma (HL), according...

Long-Term FOLL05-Up: R-CHOP Outperforms R-FM and R-CVP for Advanced-Stage Follicular Lymphoma

In 2005, the FOLL05 trial sought to determine the optimal immunochemotherapy (ICT) regimen for firstline treatment of advanced-stage follicular lymphoma (FL): R-CVP (rituximab, cyclophosphamide,...
Advertisement

Current Issue

August 2018, Volume 4, Issue 10

This issue features a look at direct-to-consumer pharmaceutical advertising, advice to graduating hematologists, and more.